POM PROM: Pitocin or Oral Misoprostol for PROM IOL

Sponsor
University of Pennsylvania (Other)
Overall Status
Recruiting
CT.gov ID
NCT04028765
Collaborator
(none)
155
1
2
49.6
3.1

Study Details

Study Description

Brief Summary

Premature rupture of membranes (PROM) is a common occurrence of pregnancies at term. A delay from PROM to labor is associated with an increased risk of intrauterine infection and associated maternal and fetal morbidity; therefore, induction of labor (IOL) is recommended. The ideal agent for IOL is not known, particularly among specific subpopulations. The primary aim of this study is to determine if oxytocin (Pitocin) or oral misoprostol results in a shorter interval to delivery after the start of induction among nulliparous women with unfavorable cervical exams with term PROM.

Condition or Disease Intervention/Treatment Phase
Phase 4

Detailed Description

Premature rupture of membranes (PROM) occurs in approximately 8% of pregnancies at term.1 Although onset of spontaneous labor is often prompt after membrane rupture, a delay from PROM to labor is associated with an increased risk of intrauterine infection and its associated maternal and fetal complications. For this reason, ACOG endorses induction of labor for PROM "if spontaneous labor does not occur near the time of presentation."

The optimal method for PROM induction is less clear. Prior literature has examined the use of Pitocin (Oxytocin), vaginal and oral misoprostol, and dinoprost with mixed results. The TermPROM study found an increased risk of chorioamnionitis and NICU admission among women treated with vaginal misoprostol for induction.

The postulated link between vaginal misoprostol and chorioamnionitis is the need for vaginal examination for placement of the misoprostol; more vaginal examinations could potentially increase the risk for infection. Utilizing oral misoprostol would eliminate the need for a vaginal exam for administration, thereby potentially mitigating this risk of infection. Currently, vaginal and oral misoprostol as well as oxytocin are used routinely in clinical care based on provider discretion.

Among 7 randomized controlled trials examining the use of oral misoprostol as compared to oxytocin, two found oral misoprostol to result in faster induction to delivery, two found oxytocin to result in faster deliveries, and the remaining three found no difference between the two.3-9 These studies are limited by small sample size, inadequate reporting of patient demographics, varied misoprostol and oxytocin protocols, and inconsistent primary outcomes. Therefore, the utility of oral misoprostol in this population has not been established. Furthermore, its efficacy in specific patient populations is unreported in the literature.

The primary aim of this study is to determine if oxytocin or oral misoprostol results in a shorter interval to delivery after the start of induction among nulliparous women with unfavorable cervical exams with PROM.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
155 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
POM PROM: Pitocin or Oral Misoprostol for PROM IOL in Nulliparous Women With Unfavorable Cervical Exams
Actual Study Start Date :
Aug 12, 2019
Anticipated Primary Completion Date :
Aug 30, 2023
Anticipated Study Completion Date :
Sep 30, 2023

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Oral Misoprostol

Oral misoprostol 50 mcg q4H for up to 6 doses or until cervical ripening is no longer indicated

Drug: Misoprostol
As above

Active Comparator: Oxytocin

IV Oxytocin 2mU/min, increased by 2mU/min q15 minutes per hospital protocol

Drug: Oxytocin
As above

Outcome Measures

Primary Outcome Measures

  1. Time from IOL to delivery [Enrollment to Delivery]

    Time (hours) from start of IOL to delivery

Secondary Outcome Measures

  1. Infection [Enrollment to Delivery]

    Suspected intraamniotic infection

  2. Time from PROM to delivery [Enrollment to Delivery]

    Time (hours) from PROM to delivery

  3. Time from IOL to vaginal delivery [Enrollment to Delivery]

    Time (hours) from PROM to delivery

  4. Time from PROM to vaginal delivery [Enrollment to Delivery]

    Time (hours) from PROM to vaginal delivery

  5. Cesarean delivery [Enrollment to Delivery]

    Cesarean section rate

  6. Maternal morbidity [Enrollment to 1 week postpartum]

    Composite maternal morbidity: postpartum hemorrhage, blood transfusion, endometritis, wound infection, VTE, hysterectomy, ICU admission, readmission within 1 week, death

  7. Neonatal Morbidity [Enrollment to 1 week postpartum]

    Composite neonatal morbidity: Neonatal intensive care (ICN) admission > 48 hours, neonatal blood transfusion, hypoxic ischemic encephalopathy, intraventricular hemorrhage grade III or IV, headcooling, severe respiratory distress syndrome, necrotizing enterocolitis, sepsis, death

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • English Speaking

  • PROM </= 24 hours with no evidence of labor

  • /= 36 weeks gestation

  • Agreeable to induction of labor

  • Nulliparous

  • Singleton pregnancy

  • Vertex presentation

  • Cervical dilation </=2 cm AND Bishop score < 8

Exclusion Criteria:
  • Prior cesarean section

  • Other contraindication to vaginal delivery

  • Intrauterine Fetal Demise

  • Major Congenital Anomaly

  • Intraamniotic infection diagnosed at time of admission

  • 36 weeks - 36 weeks and 6 days with unknown GBS status

Contacts and Locations

Locations

Site City State Country Postal Code
1 Hospital of the University of Pennsylvania Philadelphia Pennsylvania United States 19104

Sponsors and Collaborators

  • University of Pennsylvania

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Lisa Levine, Assistant Professor, University of Pennsylvania
ClinicalTrials.gov Identifier:
NCT04028765
Other Study ID Numbers:
  • 833536
First Posted:
Jul 23, 2019
Last Update Posted:
Jul 20, 2022
Last Verified:
Jul 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
Yes
Studies a U.S. FDA-regulated Device Product:
No
Product Manufactured in and Exported from the U.S.:
Yes
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 20, 2022